DiaMedica Therapeutics Reports Q2 2025 Financial Results and Positive Phase 2 Interim Data for DM199 in Preeclampsia

DiaMedica Therapeutics Inc.

Phase 2 Part 1a interim data (n=28) showed statistically significant reductions in blood pressure and uterine artery pulsatility index with no placental transfer of DM199.
Raised $30.1 million in July 2025 private placement, extending proforma cash to ~$60M and funding operations into H2 2027.
ReMEDy2 Phase 2/3 trial for acute ischemic stroke enrollment progressing; interim analysis on first 200 patients expected Q2 2026.
Appointed Julie Krop, MD, as Chief Medical Officer in August 2025; added to Russell 2000 and 3000 Indexes in June 2025.
Net loss for Q2 2025 was $7.7 million, up from $5.1 million in Q2 2024; R&D expenses increased to $5.8 million.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.